Survival outcome in patients with metastatic castration-resistant prostate cancer according to first-line treatment.

Marine Gross-Goupil,Nicolas H. Thurin,Magali Rouyer,Jérémy Jové,Thibaud Haaser,Xavier Rebillard,Michel Soulie,Gérard de Pouvourville,Marie Pierrès,Camille Capone,S. Lamarque,Emmanuelle Bignon,Cécile Droz-Perroteau,Nicholas Moore,Patrick Blin

Survival outcome in patients with metastatic castration-resistant prostate cancer according to first-line treatment.

2020

Marine Gross-Goupil
Nicolas H. Thurin
Magali Rouyer
Jérémy Jové
Thibaud Haaser
Xavier Rebillard
Michel Soulie
Gérard de Pouvourville
Marie Pierrès
Camille Capone
S. Lamarque
Emmanuelle Bignon
Cécile Droz-Perroteau
Nicholas Moore
Patrick Blin

5570Background: Therapeutic strategy in metastatic castration-resistant prostate cancer (mCRPC) has evolved significantly with the introduction of abiraterone acetate in association with prednisone...

Keywords:

survival outcome
Oncology
Internal medicine
first line treatment
castration resistant
in patient
Prostate cancer
Pathology
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations